# A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)

> **NCT04135352** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 35 (actual)

## Conditions studied

- Neoplasm Metastasis

## Interventions

- **DRUG:** 200 mg of pembrolizumab
- **BIOLOGICAL:** V938

## Key facts

- **NCT ID:** NCT04135352
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-04
- **Primary completion:** 2022-08-24
- **Final completion:** 2022-08-24
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04135352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04135352, "A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04135352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*